We have located links that may give you full text access.
Discovery of New CDK8/CycC ligands with a Novel Virtual Screening Tool.
ChemMedChem 2018 November 8
Selective inhibition of Cyclin-dependent kinase 8 and cyclin C (CDK8/CycC) has been suggested as a promising strategy for reducing mitogenic signals in cancer cells with reduced toxic effects on normal cells. We developed a novel virtual screening protocol for drug development and applied it to discovering new CDK8/CycC type II ligands, which is likely to achieve long residence time and specificity. We first analyzed binding thermodynamics of 11 published pyrazolourea ligands using molecular dynamics simulations and a free energy calculation method, VM2, and extracted the key binding information to assist virtual screening. The urea moiety was found to be the critical structural contributor of the reference ligands. Starting with the urea moiety we conducted substructure-based searches with our newly developed Superposition and Single-Point Energy Evaluation method, followed by free energy calculations, and singled out three purchasable compounds for bio-assay testing. The ranking from the experimental result is completely consistent with the predicted rankings. A potent drug-like compound has a Kd value of 42.5 nM, which is comparable to the most potent reference ligands and provided a good starting point for further improvement. This study shows that our novel virtual screening protocol is an accurate and efficient tool for drug development.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app